1. Home
  2. ABVC vs LIXT Comparison

ABVC vs LIXT Comparison

Compare ABVC & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ABVC BioPharma Inc.

ABVC

ABVC BioPharma Inc.

HOLD

Current Price

$1.08

Market Cap

30.9M

Sector

Health Care

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

N/A

Current Price

$3.07

Market Cap

25.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ABVC
LIXT
Founded
2015
2005
Country
United States
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.9M
25.3M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
ABVC
LIXT
Price
$1.08
$3.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
48.5K
38.1K
Earning Date
03-03-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
7.14
N/A
EPS
N/A
N/A
Revenue
$509,589.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.64
52 Week High
$4.02
$6.09

Technical Indicators

Market Signals
Indicator
ABVC
LIXT
Relative Strength Index (RSI) 35.36 55.83
Support Level N/A $2.97
Resistance Level $1.67 $3.30
Average True Range (ATR) 0.12 0.24
MACD -0.01 0.05
Stochastic Oscillator 29.19 80.88

Price Performance

Historical Comparison
ABVC
LIXT

About ABVC ABVC BioPharma Inc.

ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: